Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jun 11, 2026 (4 months ago)

Medline Remedy Specialized Silicone Cream

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications; Formaldehyde levels exceeded specification.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Medline Remedy Specialized Silicone Cream (Hydraguard-D ),Manufactured for Medline Industries, LP, Three Lakes Drive, Northfield, IL 80090 2 FL OZ (59 mL) NDC 53329-159-13 4 FL OZ (118 mL) NDC 53329-159-04

Affected NDCs 53329-0159-04 53329-0159-13

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Medline
dimethicone
NDC 53329-0159
125 mg/mL Cream
Topical
Medline Industries, LP OTC
Recalling firm
BioMed Laboratories, LLC.
NDC code
53329-159-13
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0663-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other impurity / degradation recalls from 2026

All impurity / degradation recalls
Class III · Low risk

Olanzapine Tablets

Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.

Ongoing Impurity / degradation Macleods Pharmaceuticals Limited NDC 33342-068-07 D-0867-2026
Class III · Low risk

Fluphenazine Hydrochloride Tablets

Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result: 1.1 percent. Spec: 1.0 percent.

Ongoing Impurity / degradation Ajanta Pharma USA Inc NDC 27241-255-01 D-0836-2026
Class II · Moderate risk

Ramipril Capsules USP

Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Ongoing Impurity / degradation Hikma Pharmaceuticals USA INC. NDC 76282-673-01 D-0831-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-04 D-0739-2026